Prevent repeal of prescription drug reforms that lower out-of-pocket costs for seniors and families.

An amendment that would direct the Senate to prevent the repeal of prescription drug reforms that lower out-of-pocket costs for seniors and families.

Alsobrooks filed an amendment to protect prescription drug reforms that lower out-of-pocket costs for seniors and families.

Senator Alsobrooks Forces Vote Capping Child Care Costs at 7% of Income
primary · speech · model gpt-5.5

Campaign page states Alsobrooks supports the Inflation Reduction Act, which enables Medicare to negotiate certain prescription drug prices and cap insulin costs, and says she supports extending Medicare negotiation and capping drug price increases for seniors at inflation.

Establishes the underlying campaign position: protect and expand IRA prescription drug reforms that reduce out-of-pocket costs.

unresolved unknown

Angela Alsobrooks on Seniors
secondary · model gpt-5.5 · confidence 90%

Sen. Alsobrooks submitted SA 1014, a deficit-neutral reserve fund for legislation relating to reducing health care prices, including preventing repeal of drug-pricing reform provisions or increasing costs for American families; the amendment was ordered to lie on the table.

Alsobrooks took concrete legislative action early in her Senate term to preserve drug-pricing reforms, but the amendment did not advance.

partial same_term A for effort

S.Amdt.1014 to S.Con.Res.7, 119th Congress
secondary · model gpt-5.5 · confidence 92%

On passage of H.R. 1 as amended, the Senate vote result was Bill Passed, 50 yeas to 50 nays with the Vice President voting yea; Alsobrooks (D-MD) voted Nay.

Alsobrooks voted against the reconciliation bill that later became P.L. 119-21, but the bill passed despite her opposition.

partial same_term A for effort

U.S. Senate Roll Call Vote 372, H.R.1, 119th Congress, 1st Session
secondary · model gpt-5.5 · confidence 95%

CRS explains that section 71203 of P.L. 119-21 expands the orphan drug exclusion to exclude from Medicare Drug Price Negotiation Program eligibility drugs designated for one or more rare diseases or conditions, effective for the third round of negotiations starting January 1, 2028.

The core drug-price negotiation program was not repealed, but Congress enacted a change that weakens/limits the program for certain orphan drugs, so the promise was not fully achieved.

partial same_term

Health Provisions in P.L. 119-21, the FY2025 Reconciliation Law
secondary · model gpt-5.5 · confidence 90%

SA 5212 by Ms. Alsobrooks was titled a deficit-neutral reserve fund relating to preventing repeal of prescription drug reforms that lower out-of-pocket costs for seniors and families; it was ordered to lie on the table.

Alsobrooks again filed a concrete amendment matching the claim, but the record indicates submission rather than enactment.

partial same_term A for effort

Congressional Record - Senate, April 22, 2026, SA 5212
secondary · model gpt-5.5 · confidence 88%

CMS said the 2026 Part D redesign implements Inflation Reduction Act changes, including a $2,100 annual out-of-pocket threshold and changes accounting for negotiated prices taking effect for selected drugs in 2026.

As of the 2026 plan year, major IRA drug reforms lowering out-of-pocket costs and implementing negotiated prices remained in operation, supporting partial fulfillment despite later program limitations.

partial same_term

Final CY 2026 Part D Redesign Program Instructions
secondary · model gpt-5.5 · confidence 90%